SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders bought 8,459 put options on the company. This is an increase of approximately 208% compared to the typical volume of 2,742 put options.
Institutional Trading of SELLAS Life Sciences Group
A number of hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC raised its holdings in SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock worth $99,000 after purchasing an additional 15,398 shares during the period. Geode Capital Management LLC raised its stake in shares of SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company's stock worth $757,000 after buying an additional 88,183 shares during the period. Anson Funds Management LP purchased a new position in shares of SELLAS Life Sciences Group during the 3rd quarter valued at approximately $992,000. XTX Topco Ltd acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter valued at $78,000. Finally, State Street Corp grew its stake in SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after acquiring an additional 40,500 shares during the period. 17.38% of the stock is owned by hedge funds and other institutional investors.
SELLAS Life Sciences Group Price Performance
NASDAQ:SLS traded up $0.02 during trading hours on Friday, reaching $1.01. The company had a trading volume of 4,278,477 shares, compared to its average volume of 3,659,557. The firm has a market cap of $71.08 million, a PE ratio of -1.46 and a beta of 2.41. SELLAS Life Sciences Group has a 1-year low of $0.50 and a 1-year high of $1.72. The business's 50 day moving average price is $1.05 and its 200-day moving average price is $1.16.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
